JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Sana Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

4.9 -8.92

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.9

Max

5.47

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-44M

-94M

Pelno marža

-321.09

Darbuotojai

194

EBITDA

-48M

-95M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+47.58% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

609M

1.4B

Ankstesnė atidarymo kaina

13.82

Ankstesnė uždarymo kaina

4.9

Naujienos nuotaikos

By Acuity

50%

50%

168 / 373 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Sana Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-30 23:32; UTC

Karštos akcijos

Stocks to Watch: Amazon, Reddit, SPS Commerce

2025-10-30 23:02; UTC

Uždarbis

AIA Group 3Q Value of New Business Grew

2025-10-30 23:45; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

2025-10-30 23:00; UTC

Uždarbis

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

2025-10-30 22:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2025-10-30 22:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

2025-10-30 22:56; UTC

Rinkos pokalbiai

Australia Shares Shaping to Pare Recent Losses -- Market Talk

2025-10-30 22:35; UTC

Uždarbis

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

2025-10-30 22:35; UTC

Uždarbis

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

2025-10-30 22:31; UTC

Uždarbis

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

2025-10-30 22:29; UTC

Uždarbis

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

2025-10-30 22:27; UTC

Uždarbis

Minas Buenaventura 3Q EPS 66c >BVN

2025-10-30 22:27; UTC

Uždarbis

Minas Buenaventura 3Q Rev $431M >BVN

2025-10-30 22:27; UTC

Uždarbis

Minas Buenaventura 3Q Net $179M >BVN

2025-10-30 22:16; UTC

Rinkos pokalbiai
Uždarbis

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

2025-10-30 22:14; UTC

Uždarbis

Review & Preview: A Tech Earnings Storm -- Barrons.com

2025-10-30 22:00; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

2025-10-30 21:39; UTC

Uždarbis

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

2025-10-30 21:26; UTC

Uždarbis

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

2025-10-30 21:14; UTC

Rinkos pokalbiai
Uždarbis

Apple Sees Record Quarterly Services Revenue -- Market Talk

2025-10-30 21:09; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-10-30 21:09; UTC

Rinkos pokalbiai
Uždarbis

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

2025-10-30 21:04; UTC

Uždarbis

Apple Expects Big December Quarter on iPhone Upgrades -- Update

2025-10-30 21:03; UTC

Uždarbis

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

2025-10-30 21:03; UTC

Uždarbis

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

2025-10-30 21:00; UTC

Uždarbis

Eldorado Gold Skouries on Track for 1Q of 2026

2025-10-30 21:00; UTC

Uždarbis

Eldorado Gold 3Q Adj EPS 41c >EGO

2025-10-30 21:00; UTC

Uždarbis

Eldorado Gold 3Q Rev $434.7M >EGO

2025-10-30 21:00; UTC

Uždarbis

Eldorado Gold 3Q Net $56M >EGO

2025-10-30 21:00; UTC

Uždarbis

Eldorado Gold 3Q EPS 27c >EGO

Akcijų palyginimas

Kainos pokytis

Sana Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

47.58% į viršų

12 mėnesių prognozė

Vidutinis 8.25 USD  47.58%

Aukščiausias 12 USD

Žemiausias 5 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sana Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.68 / 1.87Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

168 / 373 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat